| Targeted drug therapy to overcome chemoresistance in triple-negative breast cancer M Kumari, PT Krishnamurthy, P Sola Current cancer drug targets 20 (8), 559-572, 2020 | 17 | 2020 |
| DR-5 and DLL-4 mAb functionalized SLNs of gamma-secretase inhibitors-An approach for TNBC treatment M Kumari, PT Krishnamurthy, P Sola Advanced Pharmaceutical Bulletin 11 (4), 618, 2021 | 12 | 2021 |
| Novel drug delivery systems of β2 adrenoreceptor agonists to suppress SNCA gene expression and mitochondrial oxidative stress in Parkinson’s disease management P Sola, P Krishnamurthy, PK Chintamaneni, SKSS Pindiprolu, M Kumari Expert Opinion on Drug Delivery 17 (8), 1119-1132, 2020 | 12 | 2020 |
| Neuroprotective approaches to halt Parkinson's disease progression P Sola, PT Krishnamurthy, M Kumari, G Byran, HV Gangadharappa, ... Neurochemistry International, 105380, 2022 | 10 | 2022 |
| Herbal Drug Standardization: A Systemic Review TA Suman Lamichhane1*, Bhargab Jyoti Sahariah1, Bhaswati Das2, Deepika ... Journal of Drug Delivery and Therapeutics 13 (4), 149-153, 2023 | 6 | 2023 |
| Phosphodiesterase-4 inhibition in Parkinson’s disease: molecular insights and therapeutic potential D Roy, S Balasubramanian, PT Krishnamurthy, P Sola, E Rymbai Cellular and Molecular Neurobiology 43 (6), 2713-2741, 2023 | 4 | 2023 |
| A REVIEW ON BIOLOGICAL ACTIVITIES: 1, 3, 4-THIADIAZOLE AND ITS DERIVATIVES K Hemanth, K Lakshmanan, P Kalirajan, R, G Byran | 3* | |
| Polysorbate 80 surface modified SLNs of formoterol suppress SNCA gene and mitochondrial oxidative stress in mice model of Parkinson’s disease P Sola, KK Garikapati, PT Krishnamurthy, M Kumari Scientific Reports 13 (1), 19942, 2023 | | 2023 |
| Neuroprotective approaches to halt Parkinson’s disease progression P sola, ... Neurochemistry International 158, 105380, 2022 | | 2022 |
| Influence of Etoricoxib on Pharmacokinetics and Pharmacodynamics of Glibenclamide in Rabbits K Roy, B Dahal, PS Piyongsola, G Thapa, D Bhowmik | | |
